APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatological Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dermatological Medicine Market Outlook and Growth Opportunities 2026

2 January 2026207 pages

Choose your research edition.

Industry ResearchDermatological Medicine Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatological Medicine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Dermatological Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatological Medicine Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatological Medicine Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Dermatological Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dermatological Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatological Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatological Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dermatological Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dermatological Medicine market include Chongqing Huapont Pharm Co., China National Pharmaceutical Group, Xiuzheng Pharmaceutical Group, Johnson and Johnson, Merck, Harbin Letai, Pfizer, China Resources Pharmaceutical Group and Hebei Xinglong Xili Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dermatological Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatological Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatological Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dermatological Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Dermatological Medicine Segment by Company

Chongqing Huapont Pharm Co.

China National Pharmaceutical Group

Xiuzheng Pharmaceutical Group

Johnson and Johnson

Merck

Harbin Letai

Pfizer

China Resources Pharmaceutical Group

Hebei Xinglong Xili Pharmaceutical

GSK

Bayer

AbbVie

Taisho Pharmaceutical

Reckitt Benckiser

Perrigo

LEO Pharma

Ikeda Mohando

DermaPharm A/S

Bright Future Pharmaceutical

Dermatological Medicine Segment by Type

Calcineurin Inhibitors

Anti-acne

Anti-infectives

Corticosteroids

Retinoids

Others

Dermatological Medicine Segment by Application

Psoriasis

Alopecia

Atopic Dermatitis

Herpes

Rosacea

Others

Dermatological Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Dermatological Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dermatological Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dermatological Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Dermatological Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatological Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatological Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatological Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatological Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatological Medicine industry.

Chapter 3: Detailed analysis of Dermatological Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dermatological Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dermatological Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dermatological Medicine Industry Trends Table 2. Dermatological Medicine Industry Drivers Table 3. Dermatological Medicine Industry Opportunities and Challenges Table 4. Dermatological Medicine Industry Restraints Table 5. Global Dermatological Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dermatological Medicine Revenue Share by Company (2021-2026) Table 7. Global Dermatological Medicine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Dermatological Medicine Sales Volume Share by Company (2021-2026) Table 9. Global Dermatological Medicine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dermatological Medicine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dermatological Medicine Key Company Manufacturing Base & Headquarters Table 12. Global Dermatological Medicine Company, Product Type & Application Table 13. Global Dermatological Medicine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dermatological Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Calcineurin Inhibitors Table 18. Significant Companies of Anti-acne Table 19. Significant Companies of Anti-infectives Table 20. Significant Companies of Corticosteroids Table 21. Significant Companies of Retinoids Table 22. Significant Companies of Others Table 23. Global Dermatological Medicine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Dermatological Medicine Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Dermatological Medicine Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Dermatological Medicine Sales Volume Share by Type (2021-2026) Table 27. Global Dermatological Medicine Sales Volume Share by Type (2027-2032) Table 28. Global Dermatological Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Dermatological Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Dermatological Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Dermatological Medicine Sales Value Share by Type (2021-2026) Table 32. Global Dermatological Medicine Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Psoriasis Table 34. Significant Companies of Alopecia Table 35. Significant Companies of Atopic Dermatitis Table 36. Significant Companies of Herpes Table 37. Significant Companies of Rosacea Table 38. Significant Companies of Others Table 39. Global Dermatological Medicine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Dermatological Medicine Sales Volume by Application (2021-2026) & (K Units) Table 41. Global Dermatological Medicine Sales Volume by Application (2027-2032) & (K Units) Table 42. Global Dermatological Medicine Sales Volume Share by Application (2021-2026) Table 43. Global Dermatological Medicine Sales Volume Share by Application (2027-2032) Table 44. Global Dermatological Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Dermatological Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Dermatological Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Dermatological Medicine Sales Value Share by Application (2021-2026) Table 48. Global Dermatological Medicine Sales Value Share by Application (2027-2032) Table 49. Global Dermatological Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 50. Global Dermatological Medicine Sales by Region (2021-2026) & (K Units) Table 51. Global Dermatological Medicine Sales Market Share by Region (2021-2026) Table 52. Global Dermatological Medicine Sales by Region (2027-2032) & (K Units) Table 53. Global Dermatological Medicine Sales Market Share by Region (2027-2032) Table 54. Global Dermatological Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Dermatological Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Dermatological Medicine Sales Value Share by Region (2021-2026) Table 57. Global Dermatological Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Dermatological Medicine Sales Value Share by Region (2027-2032) Table 59. Global Dermatological Medicine Market Average Price (US$/Unit) by Region (2021-2026) Table 60. Global Dermatological Medicine Market Average Price (US$/Unit) by Region (2027-2032) Table 61. Global Dermatological Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. Global Dermatological Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Dermatological Medicine Sales by Country (2021-2026) & (K Units) Table 64. Global Dermatological Medicine Sales Market Share by Country (2021-2026) Table 65. Global Dermatological Medicine Sales by Country (2027-2032) & (K Units) Table 66. Global Dermatological Medicine Sales Market Share by Country (2027-2032) Table 67. Global Dermatological Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Dermatological Medicine Sales Value Market Share by Country (2021-2026) Table 69. Global Dermatological Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Dermatological Medicine Sales Value Market Share by Country (2027-2032) Table 71. Chongqing Huapont Pharm Co. Company Information Table 72. Chongqing Huapont Pharm Co. Business Overview Table 73. Chongqing Huapont Pharm Co. Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chongqing Huapont Pharm Co. Dermatological Medicine Product Portfolio Table 75. Chongqing Huapont Pharm Co. Recent Development Table 76. China National Pharmaceutical Group Company Information Table 77. China National Pharmaceutical Group Business Overview Table 78. China National Pharmaceutical Group Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. China National Pharmaceutical Group Dermatological Medicine Product Portfolio Table 80. China National Pharmaceutical Group Recent Development Table 81. Xiuzheng Pharmaceutical Group Company Information Table 82. Xiuzheng Pharmaceutical Group Business Overview Table 83. Xiuzheng Pharmaceutical Group Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Xiuzheng Pharmaceutical Group Dermatological Medicine Product Portfolio Table 85. Xiuzheng Pharmaceutical Group Recent Development Table 86. Johnson and Johnson Company Information Table 87. Johnson and Johnson Business Overview Table 88. Johnson and Johnson Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Johnson and Johnson Dermatological Medicine Product Portfolio Table 90. Johnson and Johnson Recent Development Table 91. Merck Company Information Table 92. Merck Business Overview Table 93. Merck Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Merck Dermatological Medicine Product Portfolio Table 95. Merck Recent Development Table 96. Harbin Letai Company Information Table 97. Harbin Letai Business Overview Table 98. Harbin Letai Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Harbin Letai Dermatological Medicine Product Portfolio Table 100. Harbin Letai Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Dermatological Medicine Product Portfolio Table 105. Pfizer Recent Development Table 106. China Resources Pharmaceutical Group Company Information Table 107. China Resources Pharmaceutical Group Business Overview Table 108. China Resources Pharmaceutical Group Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. China Resources Pharmaceutical Group Dermatological Medicine Product Portfolio Table 110. China Resources Pharmaceutical Group Recent Development Table 111. Hebei Xinglong Xili Pharmaceutical Company Information Table 112. Hebei Xinglong Xili Pharmaceutical Business Overview Table 113. Hebei Xinglong Xili Pharmaceutical Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Hebei Xinglong Xili Pharmaceutical Dermatological Medicine Product Portfolio Table 115. Hebei Xinglong Xili Pharmaceutical Recent Development Table 116. GSK Company Information Table 117. GSK Business Overview Table 118. GSK Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. GSK Dermatological Medicine Product Portfolio Table 120. GSK Recent Development Table 121. Bayer Company Information Table 122. Bayer Business Overview Table 123. Bayer Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Bayer Dermatological Medicine Product Portfolio Table 125. Bayer Recent Development Table 126. AbbVie Company Information Table 127. AbbVie Business Overview Table 128. AbbVie Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. AbbVie Dermatological Medicine Product Portfolio Table 130. AbbVie Recent Development Table 131. Taisho Pharmaceutical Company Information Table 132. Taisho Pharmaceutical Business Overview Table 133. Taisho Pharmaceutical Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Taisho Pharmaceutical Dermatological Medicine Product Portfolio Table 135. Taisho Pharmaceutical Recent Development Table 136. Reckitt Benckiser Company Information Table 137. Reckitt Benckiser Business Overview Table 138. Reckitt Benckiser Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Reckitt Benckiser Dermatological Medicine Product Portfolio Table 140. Reckitt Benckiser Recent Development Table 141. Perrigo Company Information Table 142. Perrigo Business Overview Table 143. Perrigo Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Perrigo Dermatological Medicine Product Portfolio Table 145. Perrigo Recent Development Table 146. LEO Pharma Company Information Table 147. LEO Pharma Business Overview Table 148. LEO Pharma Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. LEO Pharma Dermatological Medicine Product Portfolio Table 150. LEO Pharma Recent Development Table 151. Ikeda Mohando Company Information Table 152. Ikeda Mohando Business Overview Table 153. Ikeda Mohando Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Ikeda Mohando Dermatological Medicine Product Portfolio Table 155. Ikeda Mohando Recent Development Table 156. DermaPharm A/S Company Information Table 157. DermaPharm A/S Business Overview Table 158. DermaPharm A/S Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. DermaPharm A/S Dermatological Medicine Product Portfolio Table 160. DermaPharm A/S Recent Development Table 161. Bright Future Pharmaceutical Company Information Table 162. Bright Future Pharmaceutical Business Overview Table 163. Bright Future Pharmaceutical Dermatological Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Bright Future Pharmaceutical Dermatological Medicine Product Portfolio Table 165. Bright Future Pharmaceutical Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Dermatological Medicine Distributors List Table 169. Dermatological Medicine Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Dermatological Medicine Product Image Figure 2. Global Dermatological Medicine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatological Medicine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dermatological Medicine Sales (2021-2032) & (K Units) Figure 5. Global Dermatological Medicine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dermatological Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Calcineurin Inhibitors Image Figure 10. Anti-acne Image Figure 11. Anti-infectives Image Figure 12. Corticosteroids Image Figure 13. Retinoids Image Figure 14. Others Image Figure 15. Global Dermatological Medicine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Dermatological Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Dermatological Medicine Sales Volume Share by Type (2021-2032) Figure 18. Global Dermatological Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Dermatological Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Dermatological Medicine Sales Value Share by Type (2021-2032) Figure 21. Psoriasis Image Figure 22. Alopecia Image Figure 23. Atopic Dermatitis Image Figure 24. Herpes Image Figure 25. Rosacea Image Figure 26. Others Image Figure 27. Global Dermatological Medicine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Dermatological Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Dermatological Medicine Sales Volume Share by Application (2021-2032) Figure 30. Global Dermatological Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Dermatological Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Dermatological Medicine Sales Value Share by Application (2021-2032) Figure 33. Global Dermatological Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 34. Global Dermatological Medicine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Dermatological Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Dermatological Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Dermatological Medicine Sales Value (2021-2032) & (US$ Million) Figure 38. North America Dermatological Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Dermatological Medicine Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Dermatological Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Dermatological Medicine Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Dermatological Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Dermatological Medicine Sales Value (2021-2032) & (US$ Million) Figure 44. South America Dermatological Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Dermatological Medicine Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Dermatological Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Dermatological Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Dermatological Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Dermatological Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Dermatological Medicine Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Dermatological Medicine Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Calcineurin Inhibitors
  • Anti-acne
  • Anti-infectives
  • Corticosteroids
  • Retinoids
  • Others
Applications
  • Psoriasis
  • Alopecia
  • Atopic Dermatitis
  • Herpes
  • Rosacea
  • Others
Companies covered
  • Chongqing Huapont Pharm Co.
  • China National Pharmaceutical Group
  • Xiuzheng Pharmaceutical Group
  • Johnson and Johnson
  • Merck
  • Harbin Letai
  • Pfizer
  • China Resources Pharmaceutical Group
  • Hebei Xinglong Xili Pharmaceutical
  • GSK
  • Bayer
  • AbbVie
  • Taisho Pharmaceutical
  • Reckitt Benckiser
  • Perrigo
  • LEO Pharma
  • Ikeda Mohando
  • DermaPharm A/S
  • Bright Future Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dermatological Medicine Sales Value (2021-2032)
  4. 1.2.2 Global Dermatological Medicine Sales Volume (2021-2032)
  5. 1.2.3 Global Dermatological Medicine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dermatological Medicine Market Dynamics
  1. 2.1 Dermatological Medicine Industry Trends
  2. 2.2 Dermatological Medicine Industry Drivers
  3. 2.3 Dermatological Medicine Industry Opportunities and Challenges
  4. 2.4 Dermatological Medicine Industry Restraints
3 Dermatological Medicine Market by Company
  1. 3.1 Global Dermatological Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Dermatological Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Dermatological Medicine Sales Volume by Company (2021-2026)
  4. 3.4 Global Dermatological Medicine Average Price by Company (2021-2026)
  5. 3.5 Global Dermatological Medicine Company Ranking (2024-2026)
  6. 3.6 Global Dermatological Medicine Company Manufacturing Base and Headquarters
  7. 3.7 Global Dermatological Medicine Company Product Type and Application
  8. 3.8 Global Dermatological Medicine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dermatological Medicine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dermatological Medicine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dermatological Medicine Market by Type
  1. 4.1 Dermatological Medicine Type Introduction
  2. 4.1.1 Calcineurin Inhibitors
  3. 4.1.2 Anti-acne
  4. 4.1.3 Anti-infectives
  5. 4.1.4 Corticosteroids
  6. 4.1.5 Retinoids
  7. 4.1.6 Others
  8. 4.2 Global Dermatological Medicine Sales Volume by Type
  9. 4.2.1 Global Dermatological Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Dermatological Medicine Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Dermatological Medicine Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Dermatological Medicine Sales Value by Type
  13. 4.3.1 Global Dermatological Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Dermatological Medicine Sales Value by Type (2021-2032)
  15. 4.3.3 Global Dermatological Medicine Sales Value Share by Type (2021-2032)
5 Dermatological Medicine Market by Application
  1. 5.1 Dermatological Medicine Application Introduction
  2. 5.1.1 Psoriasis
  3. 5.1.2 Alopecia
  4. 5.1.3 Atopic Dermatitis
  5. 5.1.4 Herpes
  6. 5.1.5 Rosacea
  7. 5.1.6 Others
  8. 5.2 Global Dermatological Medicine Sales Volume by Application
  9. 5.2.1 Global Dermatological Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Dermatological Medicine Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Dermatological Medicine Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Dermatological Medicine Sales Value by Application
  13. 5.3.1 Global Dermatological Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Dermatological Medicine Sales Value by Application (2021-2032)
  15. 5.3.3 Global Dermatological Medicine Sales Value Share by Application (2021-2032)
6 Dermatological Medicine Regional Sales and Value Analysis
  1. 6.1 Global Dermatological Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatological Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Dermatological Medicine Sales by Region: 2021-2026
  4. 6.2.2 Global Dermatological Medicine Sales by Region (2027-2032)
  5. 6.3 Global Dermatological Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dermatological Medicine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dermatological Medicine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dermatological Medicine Sales Value by Region (2027-2032)
  9. 6.5 Global Dermatological Medicine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dermatological Medicine Sales Value (2021-2032)
  12. 6.6.2 North America Dermatological Medicine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dermatological Medicine Sales Value (2021-2032)
  15. 6.7.2 Europe Dermatological Medicine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dermatological Medicine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dermatological Medicine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dermatological Medicine Sales Value (2021-2032)
  21. 6.9.2 South America Dermatological Medicine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dermatological Medicine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dermatological Medicine Sales Value Share by Country, 2025 VS 2032
7 Dermatological Medicine Country-level Sales and Value Analysis
  1. 7.1 Global Dermatological Medicine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dermatological Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dermatological Medicine Sales by Country (2021-2032)
  4. 7.3.1 Global Dermatological Medicine Sales by Country (2021-2026)
  5. 7.3.2 Global Dermatological Medicine Sales by Country (2027-2032)
  6. 7.4 Global Dermatological Medicine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dermatological Medicine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dermatological Medicine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dermatological Medicine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dermatological Medicine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dermatological Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dermatological Medicine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dermatological Medicine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dermatological Medicine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dermatological Medicine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dermatological Medicine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dermatological Medicine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dermatological Medicine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dermatological Medicine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dermatological Medicine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dermatological Medicine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dermatological Medicine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dermatological Medicine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dermatological Medicine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dermatological Medicine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dermatological Medicine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dermatological Medicine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dermatological Medicine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dermatological Medicine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dermatological Medicine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dermatological Medicine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dermatological Medicine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dermatological Medicine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dermatological Medicine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dermatological Medicine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dermatological Medicine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dermatological Medicine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dermatological Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Huapont Pharm Co.
  2. 8.1.1 Chongqing Huapont Pharm Co. Company Information
  3. 8.1.2 Chongqing Huapont Pharm Co. Business Overview
  4. 8.1.3 Chongqing Huapont Pharm Co. Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Huapont Pharm Co. Dermatological Medicine Product Portfolio
  6. 8.1.5 Chongqing Huapont Pharm Co. Recent Developments
  7. 8.2 China National Pharmaceutical Group
  8. 8.2.1 China National Pharmaceutical Group Company Information
  9. 8.2.2 China National Pharmaceutical Group Business Overview
  10. 8.2.3 China National Pharmaceutical Group Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 China National Pharmaceutical Group Dermatological Medicine Product Portfolio
  12. 8.2.5 China National Pharmaceutical Group Recent Developments
  13. 8.3 Xiuzheng Pharmaceutical Group
  14. 8.3.1 Xiuzheng Pharmaceutical Group Company Information
  15. 8.3.2 Xiuzheng Pharmaceutical Group Business Overview
  16. 8.3.3 Xiuzheng Pharmaceutical Group Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Xiuzheng Pharmaceutical Group Dermatological Medicine Product Portfolio
  18. 8.3.5 Xiuzheng Pharmaceutical Group Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Dermatological Medicine Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Dermatological Medicine Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Harbin Letai
  32. 8.6.1 Harbin Letai Company Information
  33. 8.6.2 Harbin Letai Business Overview
  34. 8.6.3 Harbin Letai Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Harbin Letai Dermatological Medicine Product Portfolio
  36. 8.6.5 Harbin Letai Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Dermatological Medicine Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 China Resources Pharmaceutical Group
  44. 8.8.1 China Resources Pharmaceutical Group Company Information
  45. 8.8.2 China Resources Pharmaceutical Group Business Overview
  46. 8.8.3 China Resources Pharmaceutical Group Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 China Resources Pharmaceutical Group Dermatological Medicine Product Portfolio
  48. 8.8.5 China Resources Pharmaceutical Group Recent Developments
  49. 8.9 Hebei Xinglong Xili Pharmaceutical
  50. 8.9.1 Hebei Xinglong Xili Pharmaceutical Company Information
  51. 8.9.2 Hebei Xinglong Xili Pharmaceutical Business Overview
  52. 8.9.3 Hebei Xinglong Xili Pharmaceutical Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hebei Xinglong Xili Pharmaceutical Dermatological Medicine Product Portfolio
  54. 8.9.5 Hebei Xinglong Xili Pharmaceutical Recent Developments
  55. 8.10 GSK
  56. 8.10.1 GSK Company Information
  57. 8.10.2 GSK Business Overview
  58. 8.10.3 GSK Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GSK Dermatological Medicine Product Portfolio
  60. 8.10.5 GSK Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Dermatological Medicine Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 AbbVie
  68. 8.12.1 AbbVie Company Information
  69. 8.12.2 AbbVie Business Overview
  70. 8.12.3 AbbVie Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 AbbVie Dermatological Medicine Product Portfolio
  72. 8.12.5 AbbVie Recent Developments
  73. 8.13 Taisho Pharmaceutical
  74. 8.13.1 Taisho Pharmaceutical Company Information
  75. 8.13.2 Taisho Pharmaceutical Business Overview
  76. 8.13.3 Taisho Pharmaceutical Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Taisho Pharmaceutical Dermatological Medicine Product Portfolio
  78. 8.13.5 Taisho Pharmaceutical Recent Developments
  79. 8.14 Reckitt Benckiser
  80. 8.14.1 Reckitt Benckiser Company Information
  81. 8.14.2 Reckitt Benckiser Business Overview
  82. 8.14.3 Reckitt Benckiser Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Reckitt Benckiser Dermatological Medicine Product Portfolio
  84. 8.14.5 Reckitt Benckiser Recent Developments
  85. 8.15 Perrigo
  86. 8.15.1 Perrigo Company Information
  87. 8.15.2 Perrigo Business Overview
  88. 8.15.3 Perrigo Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Perrigo Dermatological Medicine Product Portfolio
  90. 8.15.5 Perrigo Recent Developments
  91. 8.16 LEO Pharma
  92. 8.16.1 LEO Pharma Company Information
  93. 8.16.2 LEO Pharma Business Overview
  94. 8.16.3 LEO Pharma Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 LEO Pharma Dermatological Medicine Product Portfolio
  96. 8.16.5 LEO Pharma Recent Developments
  97. 8.17 Ikeda Mohando
  98. 8.17.1 Ikeda Mohando Company Information
  99. 8.17.2 Ikeda Mohando Business Overview
  100. 8.17.3 Ikeda Mohando Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Ikeda Mohando Dermatological Medicine Product Portfolio
  102. 8.17.5 Ikeda Mohando Recent Developments
  103. 8.18 DermaPharm A/S
  104. 8.18.1 DermaPharm A/S Company Information
  105. 8.18.2 DermaPharm A/S Business Overview
  106. 8.18.3 DermaPharm A/S Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 DermaPharm A/S Dermatological Medicine Product Portfolio
  108. 8.18.5 DermaPharm A/S Recent Developments
  109. 8.19 Bright Future Pharmaceutical
  110. 8.19.1 Bright Future Pharmaceutical Company Information
  111. 8.19.2 Bright Future Pharmaceutical Business Overview
  112. 8.19.3 Bright Future Pharmaceutical Dermatological Medicine Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bright Future Pharmaceutical Dermatological Medicine Product Portfolio
  114. 8.19.5 Bright Future Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dermatological Medicine Value Chain Analysis
  2. 9.1.1 Dermatological Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dermatological Medicine Sales Mode & Process
  6. 9.2 Dermatological Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dermatological Medicine Distributors
  9. 9.2.3 Dermatological Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst